BIOMAT Database Logo BIOMAT Database Logo

Residual Viremia Is Linked to a Specific Immune Activation Profile in HIV-1-Infected Adults Under Efficient Antiretroviral Therapy. 2021

Mehwish Younas, and Christina Psomas, and Christelle Reynes, and Renaud Cezar, and Lucy Kundura, and Pierre Portalès, and Corinne Merle, and Nadine Atoui, and Céline Fernandez, and Vincent Le Moing, and Claudine Barbuat, and Albert Sotto, and Robert Sabatier, and Audrey Winter, and Pascale Fabbro, and Thierry Vincent, and Jacques Reynes, and Pierre Corbeau
Institute for Human Genetics, CNRS, Montpellier, France.

Chronic immune activation persists in persons living with HIV-1 even though they are aviremic under antiretroviral therapy, and fuels comorbidities. In previous studies, we have revealed that virologic responders present distinct profiles of immune activation, and that one of these profiles is related to microbial translocation. In the present work, we tested in 140 HIV-1-infected adults under efficient treatment for a mean duration of eight years whether low-level viremia might be another cause of immune activation. We observed that the frequency of viremia between 1 and 20 HIV-1 RNA copies/mL (39.5 ± 24.7% versus 21.1 ± 22.5%, p = 0.033) and transient viremia above 20 HIV-1 RNA copies/mL (15.1 ± 16.9% versus 3.3 ± 7.2%, p = 0.005) over the 2 last years was higher in patients with one profile of immune activation, Profile E, than in the other patients. Profile E, which is different from the profile related to microbial translocation with frequent CD38+ CD8+ T cells, is characterized by a high level of CD4+ T cell (cell surface expression of CD38), monocyte (plasma concentration of soluble CD14), and endothelium (plasma concentration of soluble Endothelial Protein C Receptor) activation, whereas the other profiles presented low CD4:CD8 ratio, elevated proportions of central memory CD8+ T cells or HLA-DR+ CD4+ T cells, respectively. Our data reinforce the hypothesis that various etiological factors shape the form of the immune activation in virologic responders, resulting in specific profiles. Given the type of immune activation of Profile E, a potential causal link between low-level viremia and atherosclerosis should be investigated.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D004198 Disease Susceptibility A constitution or condition of the body which makes the tissues react in special ways to certain extrinsic stimuli and thus tends to make the individual more than usually susceptible to certain diseases. Diathesis,Susceptibility, Disease,Diatheses,Disease Susceptibilities,Susceptibilities, Disease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081206 Duration of Therapy Planned or actual duration of various treatments or preventive measures. Duration of Treatment,Therapy Duration,Treatment Duration
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014766 Viremia The presence of viruses in the blood. Viremias
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Mehwish Younas, and Christina Psomas, and Christelle Reynes, and Renaud Cezar, and Lucy Kundura, and Pierre Portalès, and Corinne Merle, and Nadine Atoui, and Céline Fernandez, and Vincent Le Moing, and Claudine Barbuat, and Albert Sotto, and Robert Sabatier, and Audrey Winter, and Pascale Fabbro, and Thierry Vincent, and Jacques Reynes, and Pierre Corbeau
Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy.
February 2016, The Journal of infectious diseases,
Mehwish Younas, and Christina Psomas, and Christelle Reynes, and Renaud Cezar, and Lucy Kundura, and Pierre Portalès, and Corinne Merle, and Nadine Atoui, and Céline Fernandez, and Vincent Le Moing, and Claudine Barbuat, and Albert Sotto, and Robert Sabatier, and Audrey Winter, and Pascale Fabbro, and Thierry Vincent, and Jacques Reynes, and Pierre Corbeau
Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia.
January 2014, AIDS (London, England),
Mehwish Younas, and Christina Psomas, and Christelle Reynes, and Renaud Cezar, and Lucy Kundura, and Pierre Portalès, and Corinne Merle, and Nadine Atoui, and Céline Fernandez, and Vincent Le Moing, and Claudine Barbuat, and Albert Sotto, and Robert Sabatier, and Audrey Winter, and Pascale Fabbro, and Thierry Vincent, and Jacques Reynes, and Pierre Corbeau
Frailty among HIV-1 Infected Adults under Antiretroviral Therapy in Indonesia.
January 2019, Current HIV research,
Mehwish Younas, and Christina Psomas, and Christelle Reynes, and Renaud Cezar, and Lucy Kundura, and Pierre Portalès, and Corinne Merle, and Nadine Atoui, and Céline Fernandez, and Vincent Le Moing, and Claudine Barbuat, and Albert Sotto, and Robert Sabatier, and Audrey Winter, and Pascale Fabbro, and Thierry Vincent, and Jacques Reynes, and Pierre Corbeau
Residual immune activation in combined antiretroviral therapy-treated patients with maximally suppressed viremia.
January 2016, AIDS (London, England),
Mehwish Younas, and Christina Psomas, and Christelle Reynes, and Renaud Cezar, and Lucy Kundura, and Pierre Portalès, and Corinne Merle, and Nadine Atoui, and Céline Fernandez, and Vincent Le Moing, and Claudine Barbuat, and Albert Sotto, and Robert Sabatier, and Audrey Winter, and Pascale Fabbro, and Thierry Vincent, and Jacques Reynes, and Pierre Corbeau
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.
October 2009, PloS one,
Mehwish Younas, and Christina Psomas, and Christelle Reynes, and Renaud Cezar, and Lucy Kundura, and Pierre Portalès, and Corinne Merle, and Nadine Atoui, and Céline Fernandez, and Vincent Le Moing, and Claudine Barbuat, and Albert Sotto, and Robert Sabatier, and Audrey Winter, and Pascale Fabbro, and Thierry Vincent, and Jacques Reynes, and Pierre Corbeau
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.
February 2008, Journal of acquired immune deficiency syndromes (1999),
Mehwish Younas, and Christina Psomas, and Christelle Reynes, and Renaud Cezar, and Lucy Kundura, and Pierre Portalès, and Corinne Merle, and Nadine Atoui, and Céline Fernandez, and Vincent Le Moing, and Claudine Barbuat, and Albert Sotto, and Robert Sabatier, and Audrey Winter, and Pascale Fabbro, and Thierry Vincent, and Jacques Reynes, and Pierre Corbeau
Rosuvastatin Is Effective to Decrease CD8 T-Cell Activation Only in HIV-Infected Patients With High Residual T-Cell Activation Under Antiretroviral Therapy.
April 2016, Journal of acquired immune deficiency syndromes (1999),
Mehwish Younas, and Christina Psomas, and Christelle Reynes, and Renaud Cezar, and Lucy Kundura, and Pierre Portalès, and Corinne Merle, and Nadine Atoui, and Céline Fernandez, and Vincent Le Moing, and Claudine Barbuat, and Albert Sotto, and Robert Sabatier, and Audrey Winter, and Pascale Fabbro, and Thierry Vincent, and Jacques Reynes, and Pierre Corbeau
Residual immune dysfunction under antiretroviral therapy.
January 2021, Seminars in immunology,
Mehwish Younas, and Christina Psomas, and Christelle Reynes, and Renaud Cezar, and Lucy Kundura, and Pierre Portalès, and Corinne Merle, and Nadine Atoui, and Céline Fernandez, and Vincent Le Moing, and Claudine Barbuat, and Albert Sotto, and Robert Sabatier, and Audrey Winter, and Pascale Fabbro, and Thierry Vincent, and Jacques Reynes, and Pierre Corbeau
CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy.
May 2013, Journal of acquired immune deficiency syndromes (1999),
Mehwish Younas, and Christina Psomas, and Christelle Reynes, and Renaud Cezar, and Lucy Kundura, and Pierre Portalès, and Corinne Merle, and Nadine Atoui, and Céline Fernandez, and Vincent Le Moing, and Claudine Barbuat, and Albert Sotto, and Robert Sabatier, and Audrey Winter, and Pascale Fabbro, and Thierry Vincent, and Jacques Reynes, and Pierre Corbeau
Retrospective longitudinal analysis of low-level viremia among HIV-1 infected adults on antiretroviral therapy in Kenya.
September 2023, EClinicalMedicine,
Copied contents to your clipboard!